Lesopitron (E-4424) is a selective full agonist of the 5-HT1A receptor which is structurally related to the azapirones. In 2001 it was under development by Esteve as an anxiolytic for the treatment of generalized anxiety disorder (GAD). It made it to phase II clinical trials but was apparently discontinued as no new information on lesopitron has surfaced since.
{{Drugbox | IUPAC_name = 2-{4-[4-(4-chloro-1H-pyrazol-1-yl)butyl]piperazin-1-yl}pyrimidine | image = Lesopitron.png | image_class = skin-invert-image
| tradename = | pregnancy_category = | legal_status = Uncontrolled | routes_of_administration = Oral
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).